COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Memantine in Adult Autism Spectrum Disorder

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01078844
Recruitment Status : Terminated (Sponsor withdrew funds)
First Posted : March 2, 2010
Results First Posted : July 26, 2017
Last Update Posted : July 26, 2017
Forest Laboratories
Information provided by (Responsible Party):
Johns Hopkins University

Brief Summary:
The purpose of this study is to see if memantine is helpful in managing problematic symptoms in adults with autism, Asperger's disorder, or Pervasive Developmental Disorder not otherwise specified (NOS).

Condition or disease Intervention/treatment Phase
Autism Asperger's Disorder Pervasive Developmental Disorder NOS Drug: memantine Drug: Placebo Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 4 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Memantine in Adult Autism Spectrum Disorder
Actual Study Start Date : February 2010
Actual Primary Completion Date : July 2010
Actual Study Completion Date : July 2010

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Placebo Comparator: Placebo
Treatment as usual plus placebo
Drug: Placebo
Look-alike placebo

Active Comparator: memantine
Treatment as usual plus memantine
Drug: memantine
memantine 5-20 mg daily

Primary Outcome Measures :
  1. Clinical Global Impression-Scale(CGI-S) [ Time Frame: 12 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 85 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion criteria

  • Participant is currently in treatment in the Johns Hopkins Bayview Medical Center (JHBMC)
  • Participant has a diagnosis of:

    • Autistic Disorder
    • Asperger's Disorder
    • Pervasive Developmental Disorder (PDD) NOS
  • Participant meets one of the following criteria:

    • CGI-S >= 4 (CGI-S: ________)
    • Participant has the following problematic behaviors (at least one) that might be expected to benefit from memantine:

      1. _____________________________________________
      2. _____________________________________________
      3. _____________________________________________

Exclusion criteria

The patient meets none of the following criteria (mark if absent):

  • Active seizures (Patients with a history of seizures, who have been seizure-free on an antiepileptic regimen for six months or more would be eligible).
  • Rett's Syndrome or Childhood Disintegrative Disorder
  • Active treatment with an acetylcholinesterase inhibitor
  • Prior or current treatment with memantine
  • Current treatment with lamotrigine
  • Genetic, metabolic or degenerative disorder (excepting Fragile X).
  • Brain malformation or known severe brain trauma
  • Pregnancy or breastfeeding
  • Glomerular Filtration Rate (GFR) < 30 mL/min

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01078844

Layout table for location information
United States, Maryland
Johns Hopkins Bayview
Baltimore, Maryland, United States, 21287
Sponsors and Collaborators
Johns Hopkins University
Forest Laboratories
Layout table for investigator information
Principal Investigator: Eric Samstad, MD Johns Hopkins University
Layout table for additonal information
Responsible Party: Johns Hopkins University Identifier: NCT01078844    
Other Study ID Numbers: NA_00015760
First Posted: March 2, 2010    Key Record Dates
Results First Posted: July 26, 2017
Last Update Posted: July 26, 2017
Last Verified: June 2017
Keywords provided by Johns Hopkins University:
Asperger's Disorder
Pervasive Developmental Disorder NOS
Additional relevant MeSH terms:
Layout table for MeSH terms
Autistic Disorder
Autism Spectrum Disorder
Developmental Disabilities
Child Development Disorders, Pervasive
Asperger Syndrome
Pathologic Processes
Neurodevelopmental Disorders
Mental Disorders
Antiparkinson Agents
Anti-Dyskinesia Agents
Dopamine Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Excitatory Amino Acid Antagonists
Excitatory Amino Acid Agents